Manulife (Manufacturers Life Insurance)’s Lyell Immunopharma LYEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-24,419
Closed -$216K 2964
2025
Q2
$216K Sell
24,419
-1,272
-5% -$11.6K ﹤0.01% 2519
2025
Q1
$276K Sell
25,691
-1,902
-7% -$23.3K ﹤0.01% 2371
2024
Q4
$353K Sell
27,593
-35
-0.1% -$694 ﹤0.01% 2386
2024
Q3
$763K Sell
27,628
-30
-0.1% -$882 ﹤0.01% 2057
2024
Q2
$802K Buy
27,658
+3,485
+14% +$166K ﹤0.01% 1965
2024
Q1
$1.08M Buy
24,173
+957
+4% +$41K ﹤0.01% 1826
2023
Q4
$901K Hold
23,216
﹤0.01% 1852
2023
Q3
$683K Buy
23,216
+22
+0.1% +$1.04K ﹤0.01% 1972
2023
Q2
$1.48M Buy
23,194
+11,244
+94% +$622K ﹤0.01% 1501
2023
Q1
$564K Buy
11,950
+972
+9% +$52K ﹤0.01% 1936
2022
Q4
$735K Buy
10,978
+53
+0.5% +$5.26K ﹤0.01% 1761
2022
Q3
$1.61M Sell
10,925
-63
-0.6% -$8.53K ﹤0.01% 1436
2022
Q2
$1.46M Buy
10,988
+1,847
+20% +$189K ﹤0.01% 1498
2022
Q1
$961K Buy
9,141
+8,250
+926% +$1,000K ﹤0.01% 1777
2021
Q4
$135 Buy
891
+140
+19% +$31.2K ﹤0.01% 3004
2021
Q3
$222K Buy
+751
New +$225K ﹤0.01% 2909

Other funds holding LYEL

Manulife (Manufacturers Life Insurance)'s LYEL Position: Q3 2025 in Review

Manulife (Manufacturers Life Insurance) sold out of Lyell Immunopharma (LYEL) in Q3 2025, closing a stake of 24,419 shares — an estimated $216K sold.

Manulife (Manufacturers Life Insurance) first reported a position in LYEL in Q3 2021 and held it in 16 quarters. The position peaked at $1.61M in Q3 2022. 59 funds tracked by Wall St. Rank hold LYEL as of Q3 2025.

  • Manulife (Manufacturers Life Insurance) reported no remaining Lyell Immunopharma position as of Q3 2025 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 24,419 Lyell Immunopharma shares in Q3 2025, an estimated $216K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Lyell Immunopharma in Q3 2021 and held it in 16 quarters.
  • Manulife (Manufacturers Life Insurance)'s Lyell Immunopharma position peaked at $1.61M in Q3 2022.
  • 59 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2025.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q3 2025, filed 14 Nov 2025.